G Kolb1, F Safi, K Beckh, H G Beger. 1. Abteilung für Allgemeine Chirurgie der Chirurgischen Klinik und Poliklinik der Universität Ulm.
Abstract
BACKGROUND: Because of structure and biosynthesis of CA 19-9, it was postulated that patients with the Lewis phenotype Le(a-b-) are not able to synthesize CA 19-9. But some patients with Le(a-b-) on red blood cells showed elevated levels of this tumor marker. PATIENTS AND METHOD: In 164 patients suffering from benign or malignant diseases both CA 19-9 and the Lewis phenotype were determined in sera. In addition in 51 patients red blood cells were tested for Lewis substances. RESULTS: The frequencies of the different Lewis phenotypes on red blood cells were compared with the results found in sera. The prevalence of the phenotype Le(a-b-) on erythrocytes was significantly higher than in sera. In 51 patients both determinations were performed. These results were compared additionally. The phenotype Le(a-b-) found on red blood cells agreed with the results found in sera only in 30% of the cases. A loss of Lewis substances on erythrocytes could be seen both in malignant and benign diseases. Only in patients with Lewis substances found in sera elevated levels of CA 19-9 could be seen. CONCLUSION: Considering only the Lewis phenotype in sera, it could be confirmed that patients with the genotype Le(a-b-)are not able to express elevated concentrations of CA 19-9.
BACKGROUND: Because of structure and biosynthesis of CA 19-9, it was postulated that patients with the Lewis phenotype Le(a-b-) are not able to synthesize CA 19-9. But some patients with Le(a-b-) on red blood cells showed elevated levels of this tumor marker. PATIENTS AND METHOD: In 164 patients suffering from benign or malignant diseases both CA 19-9 and the Lewis phenotype were determined in sera. In addition in 51 patients red blood cells were tested for Lewis substances. RESULTS: The frequencies of the different Lewis phenotypes on red blood cells were compared with the results found in sera. The prevalence of the phenotype Le(a-b-) on erythrocytes was significantly higher than in sera. In 51 patients both determinations were performed. These results were compared additionally. The phenotype Le(a-b-) found on red blood cells agreed with the results found in sera only in 30% of the cases. A loss of Lewis substances on erythrocytes could be seen both in malignant and benign diseases. Only in patients with Lewis substances found in sera elevated levels of CA 19-9 could be seen. CONCLUSION: Considering only the Lewis phenotype in sera, it could be confirmed that patients with the genotype Le(a-b-)are not able to express elevated concentrations of CA 19-9.
Authors: B C Del Villano; S Brennan; P Brock; C Bucher; V Liu; M McClure; B Rake; S Space; B Westrick; H Schoemaker; V R Zurawski Journal: Clin Chem Date: 1983-03 Impact factor: 8.327
Authors: T Frebourg; E Bercoff; N Manchon; J Senant; J P Basuyau; P Breton; A Janvresse; P Brunelle; J Bourreille Journal: Cancer Date: 1988-12-01 Impact factor: 6.860
Authors: Min-Sik Kim; Sarada V Kuppireddy; Sruthi Sakamuri; Mukul Singal; Derese Getnet; H C Harsha; Renu Goel; Lavanya Balakrishnan; Harrys K C Jacob; Manoj K Kashyap; Shantal G Tankala; Anirban Maitra; Christine A Iacobuzio-Donahue; Elizabeth Jaffee; Michael G Goggins; Victor E Velculescu; Ralph H Hruban; Akhilesh Pandey Journal: J Proteome Res Date: 2012-10-11 Impact factor: 4.466